Mauna Kea Technologies, a leader in the field of endomicroscopy, today celebrated the listing of its shares on NYSE Euronext in Paris.
Founded in 2000, Mauna Kea Technologies designs, develops and sells innovative imaging solutions that make it possible to see tissues at the cellular level directly inside the human body and to detect abnormalities invisible to the naked eye. The company’s equipment can be used in most organs and in particular in the gastro-intestinal system and pulmonary tract. Mauna Kea Technologies has a portfolio of more than 150 patents and, owing to its flagship product Cellvizio®, is the only company in the market for endomicroscopy by miniprobe. Cellvizio® is sold in more than 20 countries and is used by hundreds of doctors.
Mauna Kea Technologies (ticker code: MKEA) was listed through the admission to trading of 8,931,945 existing shares and 3,779,342 new shares issued under a Global Offering[1], including full exercise of the extension clause. The Global Offering raised a total of €49.1 million (this amount may increase to a maximum of €56.5 million if the over-allotment option is fully exercised).
The admission and issue price of Mauna Kea Technologies shares was set at €13 per share. Market capitalization stood at approximately €165 million on the date of listing.
“The listing of Mauna Kea Technologies confirms its position as a world leader in endomicroscopy. We are very pleased to contribute to the development of this international group, specialized in the highly innovative field of medical imaging,” said Ronald Kent, Group Executive Vice President and Head of International Listings at NYSE Euronext. “This transaction will enable Mauna Kea Technologies and its shareholders to benefit from the liquidity, service quality and visibility that come with a listing on NYSE Euronext.”
Sacha Loiseau, founder and CEO of Mauna Kea Technologies, added, “We are very pleased with how successful our new listing on NYSE Euronext was. We would like to thank all of our shareholders, who believe in us and want to accompany us as we grow. This transaction constitutes a key step in giving Cellvizio® a strong worldwide sales presence. The capital we have raised gives us additional resources for carrying out our ambitious strategy, which aims to make Mauna Kea Technologies the leader in in vivo microscopic imaging.”
On the occasion of the listing, Sacha Loiseau rang the bell marking the start of European trading on NYSE Euronext, in the presence of company employees and the NYSE Euronext Listings team.
--------------------------------------------------------------------------------
[1] The Global Offering was made up of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.